Background: Dalbavancin is a novel lipoglycopeptide antibiotic that has potent in vitro activity against Gram-positive microorganisms. Methods: We performed a phase 1, open-label, multicenter study to investigate the pharmacokinetics (PK) and safety of a single dose of intravenous dalbavancin in hospitalized pediatric subjects 3 months to 11 years of age. We combined these data with previously collected adolescent PK data and performed a population PK analysis.
D
albavancin is a novel lipoglycopeptide antibiotic that exerts its antimicrobial effect by inhibiting the synthesis of bacterial cell wall peptidoglycan. It has potent in vitro activity against Grampositive microorganisms, including drug-resistant strains such as methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, Gram-positive anaerobes and most Gram-positive non-acid-fast bacilli, including Bacillus anthracis.
Dalbavancin is approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. In a phase 3 study, dalbavancin [1000 mg given intravenously (IV) on day 1 and 500 mg given IV on day 8] was shown to be as effective as linezolid (600 mg given IV or orally every 12 hours for 14 days) for the treatment of complicated skin and skin structure infections. 1 In 2 separate studies, the same 2-dose dalbavancin regimen was not inferior to twice-daily IV vancomycin (1 g or 15 mg/kg of body weight every 12 hours) with subsequent oral linezolid (600 mg every 12 hours) for the treatment of ABSSSI. 2 Also, a single dalbavancin infusion of 1500 mg was found to be as effective as the 2-dose regimen. 3 Both the single-and 2-dose regimens have been approved by the Food and Drug Administration and European Medicines Agency for the treatment of ABSSSI.1000-mg dose, the mean (% coefficient of variation) maximal drug concentration (C max ) and terminal half-life (t 1/2 ) were 287 mg/L (13.9%) and 14.4 days (16.5%), respectively. 6 In a population pharmacokinetic (PK) analysis of adult subjects mostly with skin and skin structure infections, a t 1/2 of 8.5 days was observed. 7 This long half-life and favorable clinical efficacy results led to the approval of a 2-dose regimen in adults: 1000 mg followed by 500 mg 1 week later.
There are limited data available for evaluating the use of dalbavancin in the pediatric population. One study evaluated dalbavancin PK after IV administration of a single dose in 10 adolescents 12 to 17 years of age and reported a t 1/2 of approximately 9 days, comparable exposures between 1000 mg and 15 mg/kg single doses and an acceptable safety profile. 8 We performed an open-label, multicenter study to characterize the PK and safety of dalbavancin in hospitalized children 3 months to 11 years of age. We then combined the data from this study with the previously published adolescent data to develop a population PK model that can inform dosing across pediatric age groups.
MATERIALS AND METHODS

Patient Population
This was a phase 1, open-label, multicenter (N = 10) study to investigate the PK, safety and tolerability of a single IV dose of dalbavancin in hospitalized pediatric patients with a suspected or confirmed bacterial infection (Study DUR001-106; Clinical Trials. gov No. NCT01946568). Subjects were enrolled in 3 age cohorts: 6-11 years of age, inclusive; 2 to <6 years of age and 3 months to <2 years of age. All study subjects received a single dose of dalbavancin in addition to standard of care anti-infective treatment chosen at the discretion of the treating physician. The study was reviewed and approved by the each institution's institutional review board. The first and last subjects were enrolled on August 13, 2013, and March 23, 2015, respectively.
The following study inclusion criteria were used: hospitalized subjects 3 months to 11 years of age (inclusive) who received systemic anti-infective treatment other than glycopeptide antibiotics for suspected or confirmed bacterial infections; legal guardian consent, and if required by the local institutional review board, assent from subjects in the 2 older age cohorts and subjects were expected to survive with appropriate antibiotic therapy and supportive care. Exclusion criteria were as follows: treatment with an investigational drug within 30 days, concurrent treatment with IV vancomycin, clinically significant laboratory abnormalities not associated with the underlying disease, albumin (ALB) concentration less than half the lower limit of normal, subjects that were less than 1 year of postnatal age born with a gestational age of less than 32 weeks, positive urine (or serum) pregnancy test, known hypersensitivity to glycopeptides, a calculated creatinine clearance (CrCl) <30 mL/min/1.73 m 2 (according to Schwartz method 9 ), pregnant or nursing females and cystic fibrosis. Because historical data from other antibiotics' PK suggested that alterations in drug clearance may occur in cystic fibrosis, the DUR001-106 protocol was amended to exclude cystic fibrosis after 3 subjects (2 of whom were dosed with study drug) with cystic fibrosis had already been enrolled.
We also used dalbavancin PK data collected from adolescents in a previously published clinical trial (Study A8841004). 8 Briefly, this was an open-label, multicenter study to evaluate the PK and safety of single-dose dalbavancin in adolescents 12-17 years of age. Subjects that were hospitalized and required parenteral antibiotic treatment for known or suspected Gram-positive infections were eligible for enrollment.
Drug Dosing and Sample Collection
For the current study performed in children 3 months to 11 years of age (Study DUR001-106), at study initiation, dalbavancin dosing was 15 mg/kg (not to exceed the 1000-mg adult dose) for subjects ≥5 years of age and 25 mg/kg for <5 years of age. The dosing regimen was selected using a population PK model that was developed using available adult and adolescent (Study A8841004) dalbavancin concentration versus time data. After performing an interim PK analysis with data from 18 subjects (N = 11, 6-11 years, inclusive and N = 7, 2 to <6 years), a dose of 10 mg/kg (maximum of 1000 mg) was selected for children 3 months to <2 years of age to achieve exposure comparable to adults. Dalbavancin was administered as a 30-minute IV infusion.
Whole blood samples (0.5 mL) for PK assessment were collected in tubes containing di-potassium ethylenediaminetetraacetic acid at predefined time points on days 1, 2, 7 and 28 after dalbavancin administration. On day 1, samples were collected at 0.5 hours after the end of the infusion (±5 minutes) and at 4 hours (±2 hours) and 12 hours (±2 hours) post-start-of-infusion. Additional samples were collected at 24 hours (±4 hours, day 2), 144 hours (±2 days, day 7) and 648 hours (±4 days, day 28). PK samples were collected from the arm contralateral to the infusion, but if not possible, samples (other than the 0.5-hour time point) could be drawn from the same line in which dalbavancin was infused. The whole blood samples were centrifuged at approximately 3000 rpm at 4°C for 10 minutes to harvest the plasma. Plasma samples were then frozen (−20°C freezer) within 5-10 minutes and kept frozen until analysis.
In the adolescent PK study (Study A8841004), a single dose of 1000 mg was given as a 30-minute IV infusion to subjects ≥60 kg or 15 mg/kg IV for those less than 60 kg. 8 Blood samples were collected at the following time points: predose, 0.5, 1, 2, 4, 12, 24, 48, 144 (day 6), 312 (day 13), 480 (day 20), 648 (day 27) and 1320 hours (day 55) postdose. 8 Of note, day 55 PK sample was not collected in the children enrolled in DUR001-106 because most of the drug was shown to be eliminated by day 27 in the adolescent study.
Analytical Methods
Dalbavancin plasma concentrations were measured by a commercial laboratory (Tandem Labs-a LabCorp Company, West Trenton, NJ) using a validated liquid chromatography-tandem mass spectrometry method. The following instrumentation were used: MDS Sciex API 4000 mass spectrometer (SCIEX, Thornhill, Ontario, Canada); Shimadzu SIL-5000 autosampler and LC-10ADVP pump (Shimadzu Scientific Instruments, Columbia, MD) and a Fortis Phenyl, 2.1 × 50 mm, 5 μm chromatographic column (Fortis Technologies Ltd., Cheshire, United Kingdom). A gradient mobile phase containing 0.1% formic acid (aq), methanol: acetonitrile (50:50, v:v) and acetone was used. The lower and upper limits of quantification were 0.5 and 500 μg/mL, respectively. Plasma was extracted using protein precipitation. The overall precision and accuracy for quality control samples were 1.8%-8.9% and −6.7% to −2.0%, respectively. Longterm stability studies were performed which showed that dalbavancin plasma samples were stable at 368 days when stored at −20°C. All clinical PK samples were analyzed within the validated period.
Dalbavancin concentration values that were below the quantification limit were excluded from the analysis.
Dalbavancin plasma concentrations appeared to decline in a polyphasic manner after the completion of the 30-minute IV infusion. A 3-compartment structural model with linear elimination was used to describe the data. The potential effects of clinical covariates on PK parameters were evaluated, and simplified models were constructed using only those covariates deemed most significant. To account for the growth effects, total body weight (WT) was included in the base model before the assessment of other covariates using an allometric scaling approach. 10, 11 Scaling with WT was performed on the following PK parameters: total clearance (CL), distributional clearance to peripheral compartment 1 (CL d1 ), distributional clearance to peripheral compartment 2 (CL d2 ), central volume of distribution (V c ), volume of distribution to peripheral compartment 1 (V p1 ) and volume of distribution to peripheral compartment 2 (V p2 ). The coefficients describing the relationship between WT and population PK parameters were estimated from the data.
Covariate Analysis
After accounting for body size differences using WT, the following additional covariates were explored for model inclusion: age, height, body surface area (BSA), sex, estimated CrCl and ALB. Individual values for each of these covariates were available for all study subjects. BSA was calculated using the method of Gehan and George. 12 In children 3 months to 11 years of age, CrCl was calculated from baseline serum creatinine and height using the Schwartz equation. 13 In adolescents 12 to 17 years of age, CrCl was calculated from serum creatinine, age and WT using the Cockcroft and Gault equation and then normalized to BSA. 
where base is the baseline CrCl at birth, R max is the maximum increase of CrCl, PNA is the postnatal age in months, Hill is a slope parameter and TMr corresponds to the age that achieves 50% of the maximum increase in CrCl. The fitted CrCl values obtained from this developmental submodel of renal function were then tested as a covariate in the population PK analysis. The statistical significance of covariate relationships was evaluated using a forward inclusion (P < 0.05 and change in objective function value >3.8) and backward elimination (P < 0.001 and change in objective function value >10.8) approach.
Derivation of Dalbavancin Exposure Estimates and Secondary PK Parameters
Using the dosing history and post hoc PK parameter estimates for each subject, a simulation was performed to generate a PK profile from 0 to 648 hours after the start of drug administration. Then the following dalbavancin exposure estimates and secondary PK parameters were calculated: C max , area under the dalbavancin plasma concentration versus time (AUC) from 0 to 120 hours (AUC 0-120 ), AUC from 0 to 168 hours (AUC 0-168 ), AUC from 0 to 648 hours (AUC 0-648 ), AUC from 0 to infinity (AUC 0-∞ ), steadystate volume of distribution (V ss ) and t 1/2 . AUC 0-120 , AUC 0-168 and AUC 0-648 were calculated by integrating the concentration versus time curve over the defined time interval, whereas AUC 0-∞ was calculated as dose divided by CL. V ss was calculated as the sum of fitted estimates of the 3 volumes of distribution (V c , V p1 and V p2 ). The t 1/2 was calculated using the post hoc slope of gamma phase based upon the 3-compartment model of PK equations.
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Model Evaluation
The following criteria were used to guide the model development process: evaluation of individual and population mean PK parameter estimates and their precision as measured using the percent standard error of the estimate, graphical examination of standard diagnostic plots, graphical examination of the observed and individual post hoc predicted concentration-time data, reduction in both residual and interindividual variability and comparison of the objective function value for nested models.
Using the final model, parameter precision was also assessed using a nonparametric bootstrap resampling technique. A total of 1000 resampled new datasets were created using the software SAS (version 9.4; SAS Institute, Inc., Cary, NC), and the median and 90% confidence interval (CI) of the parameter estimates were computed. Also, a visual predictive check based on 1000 simulations was performed to assess the ability of the final model to describe the observed concentration-time data.
Dosing Simulations
A virtual pediatric population was generated to perform dosing simulations. Age was simulated to approximate the uniform distributions of 1000 subjects 3 to 23 months of age and 1000 patients 2 to 18 years of age. Approximately, 50% of virtual subjects were assigned to each sex. ALB was simulated using a normal distribution with a mean of 3.25 g/dL and a standard deviation equal to 0.6 g/dL.
Then 2 Z scores were simulated from a normal distribution for each virtual subject with a mean of zero and standard deviation of 0.75. The first Z score (Z) along with the age-and gender-specific median (M), generalized coefficient of variation (S), and the power in the Box-Cox transformation (L) values from the Centers for Disease Control and Prevention growth charts 16 were used to obtain a value of height for each patient according to Equation 2 or 3.
WT was also calculated for each virtual subject using a similar approach and age-and gender-specific L, M and S values from the Centers for Disease Control and Prevention growth charts, 16 with the exception that the Z score was obtained by multiplying the first Z score by the probability of the second Z score from a normal distribution. This allowed for some variability in the height and weight percentiles, as is seen clinically.
Using the final model, Monte Carlo simulations were performed to identify pediatric dosing that visually matches dalbavancin AUC 0-120 distributions observed in a phase 3 adult program. The value of AUC 0-120 in adults receiving a single dose of 1000 mg IV dalbavancin was obtained from the phase 3 program, where the median (90% CI) was 6900 μg × h/mL (4400-10,600) (sponsor data, Durata Therapeutics-a subsidiary of Actavis plc, Branford, CT). The value of AUC 0-120 in adults receiving a single dose of 1500 mg IV dalbavancin was calculated from the 1000 mg IV AUC 0-120 estimate given that the PK is linear, where the median (90% CI) was 10,350 μg × h/mL (6600-15,900).
Safety Evaluation
All subjects that received study drug completed safety assessments, which included adverse event (AE) monitoring, clinical laboratory results, vital signs, weight measurement, physical examination findings and evaluation of concomitant medications. AE monitoring included documentation of serious and nonserious AEs, timing and severity of AEs, relationship to study drug, actions taken to resolve the AE and outcome. Both clinical and laboratory AEs were monitored. AEs were reported from the day of consent to 28 calendar days after study drug administration. Among subjects 3 months to 11 years of age, an audiologic assessment was performed by a licensed pediatric audiologist within 7 days before dalbavancin administration and repeated at day 28. Audiologic testing included distortion product otoacoustic emissions (DPOAE) and tympanograms. A few subjects also received pure tone air threshold testing (audiograms).
RESULTS
Patient Characteristics
A total of 44 subjects were enrolled; 34 in the current study (DUR001-106) and 10 in the adolescent study (A8841004). A total of 23 (7%) samples were either missing or below the quantification limit and were dropped from the analysis, including 1 subject where all plasma concentrations (N = 8) were uninterpretable because of thawing during transit to the bioanalysis laboratory. Dosing and patient demographic information for the remaining 43 subjects are presented in Table 1 . These 43 subjects contributed 311 samples for the PK analysis.
Population PK Analysis
A 3-compartment model with zero-order infusion input and first-order linear elimination described the dalbavancin PK data well. After accounting for body size differences using WT on all Values reported as median (range) or count (%). *For children 3 months to 11 years of age, CrCl was calculated using the Schwartz equation, 13 whereas for adolescents 12-17 years of age, the Cockcroft and Gault equation was used, and then values were normalized to body surface area. 14 PK parameters, the following additional covariate relationships were identified to be statistically significant during the forward covariate selection: ALB on CL and V c and CrCl on CL.
To account for reduced renal function in children less than 2 years of age, a hyperbolic sigmoidal function that describes age-varying changes in CrCl was used. The fitted values from this function were then used to account for the relationship between CrCl and CL. As expected, subjects who were 2 to 5 years of age and received a 25 mg/kg of dose had the highest exposure estimates (eg, AUC 0-120 and C max ). Also, weight-adjusted CL decreased with age. The individual post hoc PK parameters and exposure estimates of the 2 cystic fibrosis subjects were comparable to other subjects within the same age group (6-11 years).
Simulations
Monte Carlo simulations were performed using the final population PK model to identify the optimal pediatric dosing. Simulated AUC 0-120 estimates following dalbavancin dosing regimens designed to match a 1000-mg and 1500-mg adult dose are shown in Figures 4 and 5 , respectively.
Based on these results, the following age-dependent dosing regimen was found to achieve similar dalbavancin exposure to that in adults administered a 2-dose regimen (1000 mg on day 1 plus 500 mg on day 8): children 6 to <18 years of age, 12 mg/ kg on day 1 (1000 mg maximum) and 6 mg/kg on day 8 (500 mg maximum) and children 3 months to <6 years of age, 15 mg/kg (1000 mg maximum) on day 1 and 7.5 mg/kg (500 mg maximum) on day 8.
Similarly, the following age-dependent regimen was found to match adult single-dose exposure (1500 mg): children 6 to <18 years of age, 18 mg/kg (1500 mg maximum) on day 1 and children 3 months to <6 years of age, 22.5 mg/kg (1500 mg maximum) on day 1. 
Safety
For children 3 months to 11 years of age (N = 34, including the child that was excluded from the PK analysis), a total of 39 AEs occurred in 19 subjects-9 in the age 6 to 11 years cohort (N = 6, 54.5%), 23 in the age 2 to <6 years cohort (N = 9, 75.0%) and 4 in the age 3 months to <2 years cohort (N = 4, 36.4%). Among the 36 treatment-emergent AEs, 4 were considered severe, 6 were moderate and 26 were mild. Five subjects experienced a serious AE. None of the serious or severe treatment-emergent AEs was considered to be related to dalbavancin treatment. The ‡Effect of albumin on CL expressed using the following relationship: (albumin/3.7) −0.78 . §Effect of albumin on V c expressed using the following relationship: (albumin/3.7) −0.73 . CL indicates clearance; CL d1 , distributional clearance to peripheral compartment 1; CL d2 , distributional clearance to peripheral compartment 2; IIV, interindividual variability; NE, not evaluable; % SEM, percent standard error of the mean; V p1 , volume of distribution for peripheral compartment 1; V p2 , volume of distribution for peripheral compartment 2.
following AEs were deemed possibly related to dalbavancin treatment (N = 1, each): rash, diaper dermatitis, urticaria and asymptomatic hepatic enzyme elevation. One subject had infusion-site discomfort that was probably related to study treatment.
One cystic fibrosis patient, receiving concomitant medications including aztreonam and azithromycin, developed urticaria on day 11. On day 12, piperacillin/tazobactam and tobramycin were added. The subject was diagnosed with drug eruption, and the rash had completely resolved by day 78. The other cystic fibrosis patient that developed an asymptomatic hepatic enzyme elevation (day 7) had a history of aspartate aminotransferase and alanine aminotransferase elevation that had resolved spontaneously. Mildly elevated hepatic enzymes were observed on the day before the administration of the study drug. The subject had received concomitant medications that are known to cause elevation of aspartate aminotransferase and alanine aminotransferase, including ceftazidime, tobramycin and ciprofloxacin. Hepatic enzymes returned to normal by day 27. Estimates are reported as median (range) for all parameters. *V ss was calculated as the sum of the individual fitted estimates for the 3 volumes of distribution (V c , V p1 and V p2 ). AUC 0-120 indicates area under the dalbavancin plasma concentration versus time curve from time zero to 120 hours; AUC 0-168 , area under the dalbavancin plasma concentration versus time curve from time zero to 168 hours; AUC 0-648 , area under the dalbavancin plasma concentration versus time curve from time zero to 648 hours; AUC 0-inf , area under the dalbavancin plasma concentration versus time curve from time zero to infinity; C max , maximal plasma concentration; CL, clearance; CL_WT, body-weight adjusted clearance; V c , central volume of distribution; V ss , steady-state volume of distribution. V p1 , volume of distribution for peripheral compartment 1; V p2 , volume of distribution for peripheral compartment 2.
FIGURE 4.
Comparison of the simulated dalbavancin AUC 0-120 estimates in pediatric subjects of age 3 months to 18 years using various age-dependent dosing regimens to the distribution of AUC 0-120 estimates from the adult phase 3 program (dalbavancin day 1 dose of 1000 mg). The solid line and shaded area represent median and 90% confidence interval of AUC 0-120 estimates from the adult phase 3 program (dalbavancin day 1 dose of 1000 mg).
pediatric doses that match exposure observed in the adult phase 3 program following a 1-or 2-dose regimen. Based on these simulations, an increased mg/kg dosing regimen in younger subjects is suggested, which is consistent with the increased and expected weight-normalized clearance values observed in children 3 months to <6 years of age. Additionally, a shallow relationship between dalbavancin exposure (ie, AUC) and ALB was identified, which has no clinical relevance (ie, relatively small changes in exposure with varying ALB concentrations), and therefore, dalbavancin dose modification on the basis of ALB in children 3 months to <18 years is not warranted.
Dalbavancin was well tolerated in the current study, and there were no serious or severe AEs related to treatment. Also, no deaths were reported. There was no evidence of ototoxicity because of dalbavancin administration in the majority of subjects; for the remainder, no determination could be made. The safety profile we observed in children is consistent with that observed in adults.
